1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
677E9660953497DC00025893C002A4BDD
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-omnichannel-engagement-in-medical-affairs-trends-drivers-implementation?opendocument
18
19opendocument
2034.225.194.102
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Medical Affairs Medical Affairs Excellence

Omnichannel Engagement in Medical Affairs: Trends, Drivers and Implementation

ID: 5747


Features:

10 Info Graphics

13 Data Graphics

160+ Metrics

12 Narratives


Pages/Slides: 29


Published: 2023


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Omnichannel Engagement in Medical Affairs: Trends, Drivers and Implementation”

STUDY OVERVIEW

The accelerated adoption of digital solutions by biopharma companies provides unprecedented opportunities for Medical Affairs to deliver a consistent, personalized experience to stakeholders by adopting an omnichannel approach to engagement. To ensure a seamless stakeholder experience across all channels, it is important to identify the current trends and drivers of omnichannel engagement.

Best Practices, LLC conducted this benchmarking research to examine Medical Affairs’ advances in omnichannel engagement. This study examines current levels, trends, and drivers of omnichannel engagement in Medical Affairs. It also identifies the key benefits, challenges, and lessons learned in implementing omnichannel engagement programs.

KEY TOPICS

  • Current Use of Omnichannel in Medical Affairs
  • Omnichannel Maturity Levels
  • Drivers of Omnichannel Engagement Plans
  • Omnichannel Benefits and Challenges

KEY METRICS

  • Which best describes Medical Affairs group's current approach to omnichannel engagement?
  • Please indicate the level of omnichannel engagement of the Medical Affairs function
  • Which of the listed customer groups are engaged in omnichannel programs?
  • How important are each of the main drivers in leading benchmark organizations to create an omnichannel engagement plan?
  • During the past three months, what percentage of engagement has been omnichannel?

SAMPLE KEY FINDINGS

  • Current use of omnichannel in Medical Affairs: 83% of surveyed biopharma manufacturers have already implemented some form of an omnichannel engagement program within Medical Affairs. Another 15% are planning to do so. Just 2% have no plans to adopt an omnichannel model.

METHODOLOGY

Best Practices, LLC engaged 57 leaders from 43 biopharma companies in this research through a benchmark survey.

Industries Profiled:
Pharmaceutical; Biotech; Biopharmaceutical; Medical Device; Manufacturing; Consumer Products; Diagnostic; Health Care; Service; Chemical; Clinical Research; Laboratories


Companies Profiled:
AbbVie; Amgen; Apellis Pharmaceuticals; Astellas; AstraZeneca; Baxter International; Bayer; Biogen Idec; Boehringer Ingelheim; B. Braun; Cara Therapeutics; Chiesi; Cipla; Daiichi Sankyo; Eisai; Eli Lilly and Company; EVERSANA; Fidia; Genentech; General Electric; Gilead Sciences; GlaxoSmithKline ; Heron Therapeutics; Ipsen; Jazz Pharmaceuticals; Kyowa Kirin; Lupin; Lundbeck; Medexus Pharmaceuticals; Merck; Novartis; Novo Nordisk; Orchard Therapeutics; Pixacore; Provention Bio; Radius Health; Inc.; Roche; Sandoz; Sanofi; Santen; Supernus; Takeda Pharmaceuticals; Taysha Gene Therapies

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.